12 Month Price Forecast For ENTX
Distance to ENTX Price Forecasts
ENTX Price Momentum
๐ค Considering Entera (ENTX)?
Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.
Disclaimer: The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Data last updated: February 15, 2025 2:05 PM UTC
ENTX Analyst Ratings & Price Targets
Based on our analysis of 3 Wall Street analysts, ENTX has a bullish consensus with a median price target of $10.00 (ranging from $10.00 to $10.00). Currently trading at $2.43, the median forecast implies a 311.5% upside. This outlook is supported by 1 Buy, 0 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Raghuram Selvaraju at HC Wainwright & Co., projecting a 311.5% upside. Conversely, the most conservative target is provided by Raghuram Selvaraju at HC Wainwright & Co., suggesting a 311.5% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
ENTX Analyst Consensus
ENTX Price Target Range
Latest ENTX Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for ENTX.
Date | Firm | Analyst | Rating | Change | Price Target |
---|---|---|---|---|---|
Nov 11, 2024 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $10.00 |
Oct 7, 2024 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $10.00 |
Sep 27, 2024 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $10.00 |
Aug 12, 2024 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $10.00 |
Jun 5, 2024 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $10.00 |
May 14, 2024 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $10.00 |
May 13, 2024 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $10.00 |
Apr 2, 2024 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Maintains | $10.00 |
Dec 11, 2023 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $10.00 |
Sep 13, 2023 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $10.00 |
Sep 11, 2023 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $10.00 |
May 8, 2023 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $10.00 |
Apr 4, 2023 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $10.00 |
Mar 28, 2023 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $10.00 |
Sep 6, 2022 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Initiates | $10.00 |
Jul 19, 2022 | B. Riley Securities | Kalpit Patel | Buy | Maintains | $5.00 |
Jun 16, 2021 | B. Riley Securities | Buy | Initiates | $0.00 | |
Mar 22, 2021 | Aegis Capital | Buy | Initiates | $0.00 | |
Aug 3, 2018 | Maxim Group | Buy | Initiates | $0.00 |
Stocks Similar to Entera Bio Ltd
The following stocks are similar to Entera based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Entera Bio Ltd (ENTX) Financial Data
Entera Bio Ltd has a market capitalization of $89.50M with a P/E ratio of -7.8x. The company generates $99,000 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is -26.3% quarter-over-quarter, while maintaining an operating margin of -7,192.9% and return on equity of -144.7%.
Valuation Metrics
Growth & Margins
Financial Health
๐ฅ Want More High-Potential Stock Ideas?
Join 5,000+ investors getting our research on stocks with massive upside potential.

Entera Bio Ltd (ENTX) Company Overview
About Entera Bio Ltd
Develops oral peptide therapies for medical needs.
Entera Bio Ltd. operates as a clinical stage biopharmaceutical company, focusing on creating oral delivery systems for peptide and protein therapies. The company generates revenue through partnerships and collaborations, particularly leveraging its proprietary N-Tab technology to develop innovative treatments like EB613 for osteoporosis and EB612 for hypoparathyroidism, among others.
Founded in 2009 and based in Jerusalem, Israel, Entera Bio has advanced several product candidates to various stages of development, including a Phase 3 trial for its osteoanabolic therapy. The company's commitment to improving patient outcomes through non-injection therapies positions it well within the growing biopharmaceutical market.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
17
CEO
Ms. Miranda J. Toledano M.B.A.
Country
Israel
IPO Year
2018
Website
www.enterabio.comEntera Bio Ltd (ENTX) Latest News & Analysis
Entera Bio to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
19 days agoEntera Bio Ltd. (NASDAQ: ENTX) will participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference virtually on February 11-12, 2025, for investor meetings.
Entera Bio's participation in a major healthcare conference signals potential investor interest and highlights its focus on innovative drug delivery, which could impact stock performance and market perception.
Entera Bio Ltd. (NASDAQ: ENTX) reported its Q3 2024 financial results and business updates, focusing on its development of oral peptides and small therapeutic proteins.
Entera Bio's quarterly financial results and updates may signal its growth prospects and impact stock performance, influencing investment decisions in the biotech sector.
Entera Bio Ltd. (ENTX) reported a quarterly loss of $0.08 per share, exceeding the Zacks Consensus Estimate of a $0.05 loss.
Entera Bio's larger-than-expected quarterly loss may signal operational challenges, potentially impacting investor confidence and future stock performance.
Entera and OPKO Health report positive pharmacokinetic/pharmacodynamic results in their collaboration to develop an oral dual agonist for GLP-1 and glucagon peptides.
Positive PK/PD results from Entera and OPKO Health could indicate potential for a groundbreaking weight management drug, impacting market share and stock performance in the biotech sector.
Entera Bio Ltd. and OPKO Health announced positive topline PK/PD results for their oral dual agonist GLP-1/glucagon peptide aimed at treating obesity and metabolic disorders.
The collaboration between Entera Bio and OPKO could lead to a groundbreaking obesity treatment, potentially increasing their market value and attracting investor interest in the biotech sector.
Entera Bio Ltd. (ENTX) and argenex SE (ARGX) are being compared to their sector's performance for the current year. Specific performance metrics are not provided in the excerpt.
Performance comparisons reveal trends in sector strength and individual stock resilience, informing investment decisions and potential shifts in market sentiment for ENTX and ARGX.
Frequently Asked Questions About ENTX Stock
What is Entera Bio Ltd's (ENTX) stock forecast for 2025?
Based on our analysis of 3 Wall Street analysts, Entera Bio Ltd (ENTX) has a median price target of $10.00. The highest price target is $10.00 and the lowest is $10.00.
Is ENTX stock a good investment in 2025?
According to current analyst ratings, ENTX has 1 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $2.43. Always conduct your own research and consider your investment goals before making investment decisions.
What is the price prediction for ENTX stock?
Wall Street analysts predict ENTX stock could reach $10.00 in the next 12 months. This represents a 311.5% increase from the current price of $2.43. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Entera Bio Ltd's business model?
Entera Bio Ltd. operates as a clinical stage biopharmaceutical company, focusing on creating oral delivery systems for peptide and protein therapies. The company generates revenue through partnerships and collaborations, particularly leveraging its proprietary N-Tab technology to develop innovative treatments like EB613 for osteoporosis and EB612 for hypoparathyroidism, among others.
What is the highest forecasted price for ENTX Entera Bio Ltd?
The highest price target for ENTX is $10.00 from Raghuram Selvaraju at HC Wainwright & Co., which represents a 311.5% increase from the current price of $2.43.
What is the lowest forecasted price for ENTX Entera Bio Ltd?
The lowest price target for ENTX is $10.00 from Raghuram Selvaraju at HC Wainwright & Co., which represents a 311.5% increase from the current price of $2.43.
What is the overall ENTX consensus from analysts for Entera Bio Ltd?
The overall analyst consensus for ENTX is bullish. Out of 3 Wall Street analysts, 1 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $10.00.
How accurate are ENTX stock price projections?
Stock price projections, including those for Entera Bio Ltd, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.